The NexGard COMBO topical solution from Boehringer Ingelheim helps prevent tapeworms and other intestinal parasites as well as fleas, ticks, and heartworms.
Officials with the FDA have approved esafoxolaner, eprinomectin, and praziquantel topical solution (NexGard COMBO; Boehringer Ingelheim [BI]) for feline parasite protection. The once monthly topical solution is the first feline broad-spectrum protection that treats tapeworms, according to an organizational release, according to BI. The topical solution also protects cats against fleas, ticks, roundworms, hookworms, and heartworm disease, and is specially formulated for cats to help promote adherence to the treatment.1
Combining 3 active ingredients in a once-monthly application, the treatment is “easy and convenient”, according to Whit Cothern, DVM, executive director of veterinary professional services at Boehringer Ingelheim Animal Health. To further enable compliance, veterinarians can prescribe 3-dose and 6-dose presentations to best support the needs of their feline patients.1
Clinical studies have demonstrated benefits to using the combination topical solution, according to the release. Results include the following benefits1:
Kills fleas before they can lay eggs2
Each application of the topical solution contains esafoxolaner (12 mg per mL), which was specially formulated for cats to kill fleas and ticks. The product also contains eprinomectin (4 mg per mL) to prevent heartworm disease and treat and control roundworms and hookworms, and praziquantel (83 mg per mL) for the treatment and control of tapeworms.1
“NexGard COMBO is the one veterinarians and cat owners will want,” Cothern said, in the release. The combination topical solution will be available for veterinary clinics to order in May 2023.1
References